In a groundbreaking study shedding new light on the complex neurobiology of autism spectrum disorder (ASD), scientists at the Hebrew University of Jerusalem have uncovered a compelling biochemical mechanism that might explain abnormal cellular signaling pathways observed in some forms of autism. Led by Prof. Haitham Amal, the research identifies the pivotal role of nitric oxide, a small but influential molecule in nerve cell communication, as a key instigator in the dysregulation of mTOR, a major cellular growth and protein synthesis regulator. This dysregulation, driven by a biochemical modification called S-nitrosylation of the protective protein TSC2, provides a fresh lens through which the molecular underpinnings of autism can be examined and potentially targeted for intervention.
Nitric oxide usually operates quietly behind the scenes as an essential signaling molecule within the nervous system, delicately modulating the communication between neurons and supporting adaptive brain function. However, this new research suggests that in certain autism subtypes, nitric oxide’s function diverges from its usual helpful signaling role into a pathological trigger that effectively jams the cellular “traffic lights.” Central to this process is S-nitrosylation—a chemical modification where nitric oxide covalently attaches to the TSC2 protein, tagging it for accelerated degradation. The loss of TSC2, which normally acts as a molecular brake on the mTOR pathway, removes this critical inhibition, resulting in unchecked mTOR activation.
The mTOR pathway is renowned among neuroscientists for orchestrating a host of essential cellular processes, including neuron growth, synapse formation, and protein synthesis — all of which are fundamental for healthy brain development and plasticity. Dysregulation of mTOR signaling has been implicated in multiple neurodevelopmental disorders, including autism, yet how exactly risk factors and molecular signals converge to disturb this pathway has remained elusive. Through sophisticated systems-level proteomic analyses, Prof. Amal’s team pinpointed that nitric oxide-driven S-nitrosylation selectively targets mTOR-related proteins, especially TSC2, setting off a cascade that culminates in the hyperactivation of mTOR.
Subsequent laboratory experiments revealed that this aberrant modification of TSC2 prompts its degradation, significantly reducing its presence in neuronal cells. Without TSC2 functioning as a restraining force, mTOR activity surges, which could lead to anomalies in neuronal protein production and, ultimately, impair neuron function and intercellular communication. This discovery highlights a precise molecular “switch” that might be flipped to contribute to autism pathology via abnormal cellular growth signals.
Critically, the researchers demonstrated that pharmacologically inhibiting the production of nitric oxide within neurons prevented this pathological S-nitrosylation of TSC2. By dampening nitric oxide signaling, normal TSC2 levels and mTOR activity were restored, offering a glimmer of hope that modulating this pathway could reverse or improve aspects of autistic pathology. Moreover, this therapeutic avenue was further validated by engineering a version of TSC2 resistant to nitric oxide modification, which maintained its inhibitory effects on mTOR despite the presence of elevated nitric oxide — underscoring the causal relationship between TSC2 modulation and mTOR dysregulation.
Taking their findings from the bench to the bedside, the team analyzed clinical samples from children diagnosed with ASD, including those with mutations in the SHANK3 gene, a well-known genetic variant linked to autism, as well as cases of idiopathic ASD lacking a defined genetic cause. These analyses revealed reduced TSC2 protein levels alongside heightened mTOR activity, paralleling the molecular phenomena observed in experimental models. This congruence between laboratory and clinical data solidifies the real-world relevance of the nitric oxide–TSC2–mTOR pathway as a potential biomarker and therapeutic target in autism.
Prof. Amal emphasizes that although autism encompasses a vast spectrum of conditions with diverse etiologies, identifying such molecular pathways illuminates crucial nodes for focused research and intervention. “Autism is not a singular entity with one root cause,” he notes. “But by mapping out the biochemical cascades that lead from nitric oxide signaling to mTOR imbalance, we carve a path toward therapies that could specifically recalibrate cellular function in affected individuals.”
The implications of this research extend beyond merely expanding the biological understanding of ASD. By pinpointing the nitric oxide inhibitors’ potential role in rebalancing mTOR signaling, this study lays a foundation for developing targeted treatments that could mitigate or correct cellular abnormalities. Such interventions might ultimately improve neuronal communication, synapse health, and brain circuitry development, which are often disrupted in autism.
In the broader context of neurobiology, these findings reinforce the intricate interplay between chemical messengers, protein modifications, and signaling pathways that govern brain development and function. The study exemplifies how subtle biochemical changes, like S-nitrosylation, can have outsized effects on neural systems when regulatory proteins like TSC2 are impaired. This nuanced understanding opens new investigative channels, encouraging scientists to explore similar modifications in other neurodevelopmental and psychiatric disorders.
As the search for effective autism treatments continues, this research offers a promising, mechanistically informed direction. Therapeutic strategies emerging from these insights could include the design of molecules that inhibit nitric oxide synthesis, prevent S-nitrosylation of critical proteins, or stabilize protective proteins like TSC2. Such precision medicine approaches represent a paradigm shift from symptom management toward addressing the disorder’s root molecular dysfunctions.
In conclusion, Prof. Amal and his team’s work not only identifies a novel biochemical axis relevant to autism pathology but also provides hope that interventions targeting the nitric oxide-TSC2-mTOR pathway may one day alleviate aspects of the condition. As the scientific community digests these findings, further studies are poised to explore how manipulating this pathway therapeutically affects brain development and behavior in autism, potentially ushering in a new era of molecularly tailored treatments.
Subject of Research: Cells
Article Title: Nitric Oxide-Mediated S-Nitrosylation of TSC2 Drives mTOR dysregulation across Shank3 and Cntnap2 Models of Autism Spectrum Disorder
News Publication Date: 25-Feb-2026
Web References: 10.1038/s41380-026-03514-6
Keywords: Autism Spectrum Disorder, Nitric Oxide, S-Nitrosylation, TSC2, mTOR, Neurodevelopment, Protein Modification, SHANK3, Cellular Signaling, Neurochemistry
